Search

954 Result(s)
Sort by

Trailr2-cdh17-antibody-phase1-trial

Trailr2-cdh17-antibody-phase1-trial

Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Investment of 65 million euro in avian vaccines in France

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Production Insights

Production Insights

Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
View from Both Sides of the Table

View from Both Sides of the Table

Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Cooperation with The Defeat-NCD Partnership

Cooperation with The Defeat-NCD Partnership

Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Kicking off 2024 with five new R&D partnerships

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
opening-solids-launch-fabrik

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.